DK0642580T3 - Hepactocytvækstfaktorvarianter - Google Patents

Hepactocytvækstfaktorvarianter

Info

Publication number
DK0642580T3
DK0642580T3 DK93911339T DK93911339T DK0642580T3 DK 0642580 T3 DK0642580 T3 DK 0642580T3 DK 93911339 T DK93911339 T DK 93911339T DK 93911339 T DK93911339 T DK 93911339T DK 0642580 T3 DK0642580 T3 DK 0642580T3
Authority
DK
Denmark
Prior art keywords
growth factor
hepactocyte
hgf
factor variants
variants
Prior art date
Application number
DK93911339T
Other languages
English (en)
Inventor
Paul J Godowski
Nathalie A Lokker
Melanie R Mark
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/884,811 external-priority patent/US5316921A/en
Priority claimed from US07/885,971 external-priority patent/US5328837A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK0642580T3 publication Critical patent/DK0642580T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DK93911339T 1992-05-18 1993-05-17 Hepactocytvækstfaktorvarianter DK0642580T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/884,811 US5316921A (en) 1992-05-18 1992-05-18 Single-chain hepatocyte growth factor variants
US07/885,971 US5328837A (en) 1992-05-18 1992-05-18 Hepatocyte growth factor protease domain variants
PCT/US1993/004648 WO1993023541A1 (en) 1992-05-18 1993-05-17 Hepatocyte growth factor variants

Publications (1)

Publication Number Publication Date
DK0642580T3 true DK0642580T3 (da) 2002-12-23

Family

ID=27128741

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93911339T DK0642580T3 (da) 1992-05-18 1993-05-17 Hepactocytvækstfaktorvarianter

Country Status (10)

Country Link
US (1) US5547856A (da)
EP (1) EP0642580B1 (da)
JP (2) JPH07508420A (da)
AT (1) ATE222603T1 (da)
CA (1) CA2118012A1 (da)
DE (1) DE69332221T2 (da)
DK (1) DK0642580T3 (da)
ES (1) ES2181689T3 (da)
PT (1) PT642580E (da)
WO (1) WO1993023541A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566098B1 (en) 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
CA2144856A1 (en) * 1992-09-18 1994-03-31 Donna L. Faletto A method of preventing tumor metastasis
DE69531673T2 (de) * 1994-12-27 2004-07-08 Daiichi Pharmaceutical Co., Ltd. Tcf mutante
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
JP3832674B2 (ja) * 1995-10-24 2006-10-11 敏一 中村 抗癌剤
US6855685B2 (en) 1995-10-24 2005-02-15 Toshikazu Nakamura Anti-cancer agent
WO1998019696A1 (en) * 1996-11-05 1998-05-14 Smithkline Beecham Corporation Hepatocyte growth factor antagonists
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
ES2274567T3 (es) 1997-03-14 2007-05-16 Daiichi Pharmaceutical Co., Ltd. Utilizacion de tcf-ii para el tratamiento de la perdida de peso corporal, la anemia y la elevacion de tnf causadas por el cancer.
GB9709453D0 (en) * 1997-05-10 1997-07-02 Imp Cancer Res Tech Polypedtides and their use in therapy
ITMI980179A1 (it) 1998-01-30 1999-07-30 Dompe Spa Proteine ricombinanti derivate da hgf e msp
ITMI980180A1 (it) * 1998-01-30 1999-07-30 Dompe Spa Proteine ricombinanti derivate da hgf e msp
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
CA2384662A1 (en) * 1999-09-27 2001-04-05 Human Genome Sciences, Inc. 41 human secreted proteins
US20080241835A1 (en) * 1999-11-01 2008-10-02 Genentech, Inc. Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
CA2392366A1 (en) * 1999-11-24 2001-05-31 Human Genome Sciences, Inc. Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies
CA2413754C (en) * 2000-06-22 2013-07-30 Masashi Miyake Canine hepatocyte growth factor
EP1234583A1 (en) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
GB0110430D0 (en) * 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
WO2003104429A2 (en) * 2002-06-10 2003-12-18 Idec Pharmaceuticals Corporation Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
CA2499896A1 (en) * 2002-10-07 2004-04-22 Genentech, Inc. Hepatocyte growth factor variants
EP2284180B1 (en) * 2003-03-03 2015-09-09 Dyax Corp. Uses of peptides that specifically bind HGF receptor (cMET)
US7407660B2 (en) * 2003-04-16 2008-08-05 Genentech, Inc. Methods and compositions for selective modulation of vascularization
EP1695982B1 (en) * 2003-12-16 2013-01-23 Toshikazu Nakamura Glycosylation-deficient hepatocyte growth factor
AU2004309347B2 (en) * 2003-12-19 2010-03-04 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
US7807177B2 (en) * 2004-01-27 2010-10-05 Toshikazu Nakamura Segment of glycosylation-deficient HGFalpha-chain
DE602005003929T2 (de) 2004-03-03 2008-12-04 F. Hoffmann-La Roche Ag Verfahren zur aufreinigung eines n-terminalen fragments des hepatozytenwachstumsfaktors
CN1926236A (zh) 2004-03-03 2007-03-07 霍夫曼-拉罗奇有限公司 肝细胞生长因子的n－端片段的重组表达的方法
PT1773885E (pt) 2004-08-05 2010-07-21 Genentech Inc Antagonistas anti-cmet humanizados
ZA200710599B (en) 2005-04-15 2009-08-26 Genentech Inc HGF Beta chain variants
US20090226455A1 (en) * 2008-03-06 2009-09-10 Genentech, Inc. Combination therapy with c-met and her antagonists
WO2013003680A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
WO2019027299A2 (ko) * 2017-08-04 2019-02-07 주식회사 에스엘바이젠 간세포성장인자를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학 조성물
CN109535243B (zh) 2019-01-07 2019-09-24 北京诺思兰德生物技术股份有限公司 人肝细胞生长因子突变体及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2814981C3 (de) * 1978-04-07 1981-08-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Faktor zur Stimulation der Proliferationsrate von Leberzellen
DE2914903C2 (de) * 1979-04-12 1981-08-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Leberzellwachstumfaktor
JPS5862116A (ja) * 1981-10-09 1983-04-13 Mitsubishi Chem Ind Ltd 肝細胞の増殖促進物質
JPS6045534A (ja) * 1983-08-22 1985-03-12 Otsuka Pharmaceut Co Ltd 肝実質細胞増殖因子
JPS60243019A (ja) * 1984-05-17 1985-12-03 Mitsubishi Chem Ind Ltd 肝細胞増殖因子
JPH0635480B2 (ja) * 1985-08-23 1994-05-11 大塚製薬株式会社 肝実質細胞増殖因子
JPS62161730A (ja) * 1986-01-10 1987-07-17 Mitsubishi Chem Ind Ltd 細胞増殖因子の産生誘発剤
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
ES2005159A6 (es) * 1987-04-14 1989-03-01 Inst Llorente S A Procedimiento para diagnostico y seguimiento de hepatopatias mediante determinacion de factor de crecimiento hepatico en plasma yno suero sanguineo.
JPS6427491A (en) * 1987-07-14 1989-01-30 Yasushi Daikuhara Monoclonal antibody
JPH02213A (ja) * 1987-10-19 1990-01-05 Taiho Yakuhin Kogyo Kk 生理活性ペプチド持続製剤
JP3030312B2 (ja) * 1988-12-12 2000-04-10 敏一 中村 成熟肝実質細胞増殖因子（ｉ）
US5179078A (en) * 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
JPH03130091A (ja) * 1989-06-05 1991-06-03 Toyobo Co Ltd 組換ヒト肝実質細胞増殖因子
JP2706704B2 (ja) * 1989-06-05 1998-01-28 敏一 中村 組換ヒト肝実質細胞増殖因子
CA2022752C (en) * 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
JPH03204899A (ja) * 1989-09-21 1991-09-06 Otsuka Pharmaceut Co Ltd ヒト肝再生因子、そのｄｎａ塩基配列、該配列を含むプラスミド及び形質転換体並びにリコンビナント肝再生因子
JPH03255096A (ja) * 1990-03-01 1991-11-13 Toyobo Co Ltd 組換ラット肝実質細胞増殖因子
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
JPH0413696A (ja) * 1990-05-08 1992-01-17 Mochida Pharmaceut Co Ltd 新規生理活性物質
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
JPH0436189A (ja) * 1990-05-30 1992-02-06 Otsuka Pharmaceut Co Ltd 肝細胞増殖因子の製造方法
DE69133492T2 (de) * 1990-06-11 2006-08-10 Nakamura, Toshikazu Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung
JP2750372B2 (ja) * 1990-06-19 1998-05-13 敏一 中村 賢疾患治療剤
ATE178354T1 (de) * 1990-07-13 1999-04-15 Snow Brand Milk Products Co Ltd Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung
JPH04120097A (ja) * 1990-09-07 1992-04-21 Agency Of Ind Science & Technol 肝細胞増殖因子
ATE256736T1 (de) * 1990-09-14 2004-01-15 Us Health Ein nicht-mitogener kompetitiver hgf-antagonist
JP3072628B2 (ja) * 1990-11-19 2000-07-31 敏一 中村 ヒト肝実質細胞増殖因子をコードする染色体ｄｎａ
JP3200609B2 (ja) * 1990-12-28 2001-08-20 敏一 中村 上皮細胞増殖促進剤
US5328837A (en) * 1992-05-18 1994-07-12 Genentech, Inc. Hepatocyte growth factor protease domain variants
US5316921A (en) * 1992-05-18 1994-05-31 Genentech, Inc. Single-chain hepatocyte growth factor variants

Also Published As

Publication number Publication date
ES2181689T3 (es) 2003-03-01
DE69332221T2 (de) 2003-04-17
ATE222603T1 (de) 2002-09-15
PT642580E (pt) 2003-01-31
WO1993023541A1 (en) 1993-11-25
JPH07508420A (ja) 1995-09-21
DE69332221D1 (de) 2002-09-26
CA2118012A1 (en) 1993-11-25
JP2004000236A (ja) 2004-01-08
US5547856A (en) 1996-08-20
EP0642580B1 (en) 2002-08-21
EP0642580A1 (en) 1995-03-15

Similar Documents

Publication Publication Date Title
ATE222603T1 (de) Hepatozytwachstumfaktor variante
ATE274588T1 (de) Mutante alpha-amylase mit zusätzlicher disulfidverbindung
ATE77650T1 (de) Enzymatische waschmittelzusammensetzung.
ATE184289T1 (de) Ribosomen-inaktivierende proteine, inaktive vorläuferformen derselben, verfahren zur herstellung und eine methode zur nutzung
FI862756A0 (fi) Fibroektiner.
MX9804262A (es) Inhibidores derivados de d-aminoacidos de proteasas de cisteina y serina.
ES2134924T3 (es) Acidos sulfonilalcanoilamino-hidroxietilamino-sulfamicos utiles como inhibidores de proteasas retrovirales.
EP0975353A4 (en) PEPTIDYL-2-AMINO-1HYDROXYALKANESULPHONIC ACIDS AS CYSTEIN PROTEASE INHIBITORS
KR970009949B1 (en) Novel serine proteolytic enzyme and its process
UA32523C2 (uk) Пептиди, які мають високу біологічну активність, та фармацевтична композиція на їх основі
DE69333639D1 (en) Trypsininhibitoren
ATE73844T1 (de) Verfahren zur erhoehung der produktion des gewebeplasminogenaktivators und des einzelkettenurokinase-plasminogenaktivators.
DE59009945D1 (de) Mittel zur hemmung von hiv-proteasen.
ATE211169T1 (de) Dipeptidylaminopeptidase von dictyostelium
DK0757994T3 (da) TCF-mutanter
AU96847S (en) Sofa-bed
AU124219S (en) Edging
AU127561S (en) Edging
FI914674A7 (fi) Hiilidioksidin entsymaattinen määritys
GR871978B (en) Figures of grand alexanders period used as chess pieces